Compare Synchrony Financial (SYF) vs TG Therapeutics Inc (TGTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Synchrony Financial vs TG Therapeutics Inc — how do they compare? Synchrony Financial trades at $71.7 (market cap $24.69B), while TG Therapeutics Inc trades at $54.06 (market cap $8.26B). The key difference: Synchrony Financial is far larger — about 3× TG Therapeutics Inc's market cap, and Synchrony Financial pays a 1.63% dividend while TG Therapeutics Inc pays none. Which is the better fit depends on your goals.
| SYF | TGTX | |
|---|---|---|
Market Cap | $24.69B | $8.26B |
Sector | Financials | Health |
52-Week High | $88.47 | $59.06 |
52-Week Low | $63.78 | $26.39 |
Dividend Yield | 1.63% | — |
Enterprise Value | — | $8.50B |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Synchrony Financial
Synchrony Financial is a premier consumer financial services company and the largest provider of private-label credit cards in the United States. Spun off from GE Capital in 2014, it operates through a unique B2B2C model, embedding its financing products within the ecosystems of major partners like Amazon, Lowe’s, and PayPal. Synchrony leverages deep data analytics and a diverse multi-platform strategy—spanning retail, health, and auto—to drive customer loyalty and provide specialized credit solutions at the point of sale.
Read more on SYF →About TG Therapeutics Inc
TG Therapeutics is a fully integrated biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases. Its cornerstone product, BRIUMVI (ublituximab-xiiy), is a glycoengineered monoclonal antibody approved for relapsing forms of multiple sclerosis. The company is currently executing a 'pipeline-in-a-product' strategy, expanding BRIUMVI into new delivery methods and indications while advancing a broader portfolio of autoimmune and oncology candidates.
Read more on TGTX →
